MEDiSTRAVA, an Inizio Company’s Post

FUNDING NEWS: We are thrilled to announce our £90m ($114m) series A financing, one of the largest biotech series A in European biotech and the largest in the UK this year. The round was co-led by new investors Novo Holdings and Abingworth. Additional new investors British Patient Capital, Cancer Research Horizons and Eli Lilly and Company also participated alongside founding investors Brandon Capital and Sofinnova Partners. The series A funds enable us to build out our proprietary N-Myristoyltransferase inhibitor (#NMTi) antibody-drug conjugate (#ADC) payload platform and advance our pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens. The ADC area is one of the most promising modalities and new payloads are urgently needed. Having been a virtual company since spinning out from Imperial College London and The Francis Crick Institute, we will now move to establish laboratory operations in London’s biotech hub and will be expanding our management and R&D teams. Welcome to our new investors and thank you to everyone that has contributed to the progress of the company so far, not least our founding scientists Ed Tate, Roberto Solari and Andy Bell. Exciting times ahead. Read the full release HERE https://lnkd.in/eSu9mP3c #venturecapital #financing #drugdevelopment #UKbiotech

Immunophotonics, Inc. is grateful to National Cancer Institute (NCI) SBIR Investor Initiatives Team for providing us the opportunity to showcase our technology at the Global Life Science Partnering & Investor Conference presented by Biocom California taking place February 27 – 29, 2024 in La Jolla, California. Immunophotonics is thrilled to take part in this exclusive global partnering forum that unites senior executives, CEO’s, bankers, venture capitalists, and business development professionals from leading pharmaceutical and biotech companies. Be sure to catch Lu Alleruzzo, CEO of Immunophotonics’ presenting on February 28th at 3:21 pm (PST) and see how Immunophotonics is advancing the novel concept of abscopalizing routine tumor destruction procedures. “Abscopalize It!™”  If interested in a one-on-one meeting at the event, reach out to Lu directly: https://lnkd.in/gsgMjyfZ Visit us at: www.immunophotonics.com #biotech #biotechnology #research #biopharma #drugdevelopment #lifesciences #emergingmarkets #webuildbio #antibody #startups #cancerimmunity #investors #venturecaptial #vcfunding #angleinvestors #CEO #interventionaloncology #ablation #immunooncology #cancer #immunotherapy #Immunophotonics #clinicaltrials #innovation #abscopalize_it #oncology #oncologyresearch #interventionalradiology #medicaloncology #trials #healthcareexcellence

𝐀𝐫𝐬𝐞𝐧𝐚𝐥 𝐁𝐢𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐑𝐚𝐢𝐬𝐞𝐬 $325𝐌 𝐢𝐧 𝐎𝐯𝐞𝐫𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐞𝐝 𝐒𝐞𝐫𝐢𝐞𝐬 𝐂 𝐭𝐨 𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐂𝐀𝐑 𝐓-𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐟𝐨𝐫 𝐒𝐨𝐥𝐢𝐝 𝐓𝐮𝐦𝐨𝐫𝐬 Arsenal Biosciences has closed a $325 million Series C financing round. The round includes new investors like ARCH Venture Partners, Regeneron Ventures, and NVIDIA’s NVentures, along with continued support from Bristol-Myers Squibb and SoftBank Vision Fund 2. 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: • The funds will support the development of ArsenalBio’s CAR T-cell therapies for solid tumors, including ovarian, kidney, and prostate cancers. • ArsenalBio is using its advanced T-cell engineering platform to push innovation and tackle unmet needs in cancer treatment. • CEO Ken Drazan, M.D., said this funding will help scale manufacturing and explore new areas in T-cell medicine. ArsenalBio is working on next-generation T-cell therapies that use CRISPR technology for better tumor targeting and increased effectiveness. Follow us for updates on the latest biotech news in cancer research. #Biotech #CellTherapy #Oncology #CancerResearch #CAR_T

🌟 Exciting News for Biotech Innovators! 🌟 Mirae Asset Capital Life Science launches a staggering $50M fund, aiming to catalyze breakthroughs in U.S. biotech! They're fueling progress from seed to Series C, with a keen eye on combating oncology, immunology, and more. Plus, they're embracing AI for next-gen drug discovery. Already leading a $75M round for a pioneering oncology venture, the future of life sciences looks bright! Dive into the details of this groundbreaking initiative on my blog. #BiotechFunding #LifeSciences #Innovation #MiraeAssetCapital💡🧬 [Include link to the full blog post]

𝐀𝐈 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐋𝐚𝐧𝐝𝐬 𝐌𝐚𝐣𝐨𝐫 𝐅𝐮𝐧𝐝𝐢𝐧𝐠: Eric Soller Reveals Key Insights 👇 Last week, I had a fantastic catch up (as always) with Eric Soller, CBO of Outpace, who shared exciting details about their latest major funding round. Every person and even their blooming grandmother can agree it is a tough market for preclinical cell therapies, so it's certainly intriguing to see how Outpace’s AI-powered protein design has attracted oversubscribed funding from top VCs - $144M Series B, and oh boy, that’s a major win! 𝐇𝐞𝐫𝐞’𝐬 𝐖𝐡𝐚𝐭 𝐄𝐫𝐢𝐜 𝐇𝐚𝐝 𝐭𝐨 𝐒𝐚𝐲: "Our generalizable, plug-and-play technology approach de-risks our future pipeline efforts, and our capital efficiency was also a key factor for investors". 👉 Eric was thrilled to have the support of top-tier investors, including Artis Ventures, BMS and RA Capital, who recognise the potential of Outpace's unrivalled AI-powered protein design to deliver on the promise of cell therapy for solid tumours. 𝐓𝐡𝐞𝐢𝐫 𝐥𝐞𝐚𝐝 𝐚𝐬𝐬𝐞𝐭 𝐭𝐚𝐫𝐠𝐞𝐭𝐬 𝐨𝐯𝐚𝐫𝐢𝐚𝐧 𝐜𝐚𝐧𝐜𝐞𝐫, an approach I find particularly exciting, with potential applications in other areas as well. ➡️ According to Eric, the financing will "accelerate clinical development of Outpace's programmed T cell therapies and was backed by 𝘴𝘵𝘳𝘰𝘯𝘨 𝘱𝘳𝘦𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘥𝘢𝘵𝘢 for lead program, OPB-101, OPB-101 is a mesothelin-specific CAR T cell enhanced by Outpace’s proprietary 𝐎𝐔𝐓𝐒𝐌𝐀𝐑𝐓™, 𝐎𝐔𝐓𝐋𝐀𝐒𝐓™, 𝐎𝐔𝐓𝐒𝐏𝐀𝐂𝐄𝐑™, 𝐚𝐧𝐝 𝐎𝐔𝐓𝐒𝐀𝐅𝐄™ technologies to address multiple barriers to efficacy". 👏 Cheers to Eric for the great discussion, and congratulations to Outpace on securing this significant funding! #celltherapy #oncology #biotech #CGTweekly

🌟 Big News from Nucleai! We're thrilled to share a major milestone at Nucleai: the successful completion of our Series B extension, led by M Ventures , bringing our total funding to $60 million! This pivotal investment will enable us to further deploy our AI algorithms for the prospective enrollment of patients in clinical trials – a first in the field and a significant advancement in precision oncology. "M Ventures' investment boosts our ability to scale and deploy our spatial AI technology for patient enrollment in clinical trials and supports our work in the rapidly emerging areas of immunotherapies, antibody-drug conjugates, and bi-specifics," said Avi Veidman, Nucleai's CEO and Co-founder. 🙏 We're incredibly grateful for the trust and confidence our investors have placed in us. Together, we're set to transform the landscape of next-generation therapeutics. ➡️ Read the full announcement > https://bwnews.pr/3U5Jxgc #spatialbiomarkers #biomarkers #CDx #spatialbiology #digitalpathology #precisonmedicine #pressrelease #immunotherapy #precisiononcology

“Looking beyond the lampposts, looking beyond the known biology, is what Recursion’s platform promises to unlock.” ◾ The Bayer-Recursion collaboration brings together Recursion’s technology-forward and AI-leading emphasis and Bayer’s legacy of drug development. The $1.5B deal announced last October in precision oncology already has one joint project now rapidly advancing to Lead Series nomination. ◾ We are on track to complete 25 unique multimodal data packages in Q3. ◾ The Recursion operating system allows Bayer to scale up data generation, explore a large number of oncology targets simultaneously, and “do unbiased discovery.” ◾ Announced at Download Day, Bayer will be the first beta-user of our LOWE LLM-orchestrated workflow software, which will be integrated across the collaboration and offer a more exploratory and intuitive research environment for scientists on both sides. #techbio #ai #platform #partnership #pharma #cancer #oncology #downloadday

Another step towards revealing the power of spatial biology!

Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer. We are meeting the founders Marie-Agnès Doucey and Riccardo Turrini, alumni of University of Lausanne, and based at Biopôle Lausanne, in this exclusive interview for Venture Kick. Watch and be inspired: https://lnkd.in/gvBy-yDU About Calico Biosystems: Both the high attrition rate (> 95%) of therapeutics and the low response rate of patients to approved anti-cancer therapies call for a game changer in therapeutic testing. Calico Biosystems merges innovative experimental and digital approaches to assess the potency of therapeutics on patient tumours. The experimental approach uses the exclusive know-how of the founders in testing therapeutics on native patient tumours, therefore overcoming artificial models. The digital approach, based on computational modelling, predicts the most potent combinations of therapeutics to benefit patients in the clinic. Calico Biosystems' unique service provider platform will be offered to pharma & biotech companies that want to assess the efficacy of their therapeutics in pre-clinical settings, as well as hospitals and clinical trial sponsors, to identify the best combination treatment for each patient in clinics. Calico Biosystems is a 2023 alumnus of Venture Kick. Learn more: https://lnkd.in/eUMVztYk #VentureKick #SwissStartups

I am excited to announce, that ZAKA VC has invested in another ground-breaking project in the forefront of biotech. Eigen Therapeutics leads the way in redefining the precision cancer treatment. Since no two cancers are the same, there’s a need to combine therapies which are very effective. The problem is that you’re usually looking at various targets at once – so knowing which are the right ones and aiming at them precisely is the key. The more accurate your “aim” is the lesser chance is there for cancer cells to escape the treatment. This helps not only in improving outcomes for patients but also reducing the side effects of the treatment. The Eigen Therapeutics’ team, under a leadership of CEO and Co-Founder Transon Nguyen, CTO and Co-Founder Kamran A., and Chief Scientific Officer Kathryn Vanderlaag, is combining multidisciplinary knowledge and building a platform to scale co-therapy development. They’re using machine learning and automation to improve existing targeted therapies, develop new combination therapies, and make them available for a wider range of cancers. Alongside ExcepGen, Sensible Biotechnologies, and Olio Labs, Eigen Therapeutics is another great addition to ZAKA VC portfolio. The partnership with a company that already collaborates with top Silicon Valley funds continues to strengthen our commitment to advancements in the biotech sector. #newinvestment #biotech #precisionmedicine #eigentherapeutics